라트비아 - 라트비아어 - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 100 μg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 50 μg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 125 μg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 75 μg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

berlin-chemie ag, germany - levotiroksīna nātrija sāls - tablete - 25 μg

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistiskā fibroze - other respiratory system products - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistiskā fibroze - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - cukura diabēts, 2. tips - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. par pētījuma rezultātiem attiecībā uz kombināciju ietekmi uz glycaemic kontroles un sirds un asinsvadu notikumi, un populācijas izpēte, skatīt 4. 4, 4. 5 un 5.

라트비아 - 라트비아어 - Zāļu valsts aģentūra

teva b.v., netherlands - vildagliptīns - tablete - 50 mg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - dapagliflozīns - apvalkotā tablete - 5 mg